What Is the role for Interleukin-1 receptor antagonist in rheumatic disease?{lozenge, open}{lozenge, open}Pour citer cet article, utiliser ce titre en anglais et sa référence dans le même volume de Joint Bone Spine.;Quelle est la place actuelle de l'IL-1Ra dans les maladies rhumatismales ?

Revue du Rhumatisme (Edition Francaise)

Volumn 74, Issue 5, 2007, Pages 435-439

  Lequerré, Thierry ^a   Vittecoq, Olivier ^a   Le Loët, Xavier ^a  

^a INSERM   (France)

Author keywords

Interleukin 1; Rheumatoid arthritis

Indexed keywords

EID: 34147211479     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2006.10.670     Document Type: Editorial

References (33)

1. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., and Duff G.W. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2 (1988) 706-709
2. Dayer J.M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatol. 2 Suppl (2003) 3-10
3. Dayer J.M. The sage of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Rev. Rhum. 69 (2002) 123-132 [Engl Ed]
4. Vittecoq O., Jacquot S., Jouen-Beades F., Pouplin S., Thomas M., Dutot I., et al. Potential diagnostic value of IL1-RA production by whole blood cells from community-recruited patients with very early arthritis. Results of the VErA study. Arthritis Rheum. 48 Suppl (2003) 542
5. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63 (2004) 1062-1068
6. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48 (2003) 927-934
7. Le Loët X., Nordstrom D., Rodriguez M., Rubbert A., Sarzi-Puttini P., Wouters J.M.G., et al. Safety of Anakinra (Kineret) added to traditional disease-modifying antirheumatic drug therapy in patients with active rheumatoid arthritis: Results of the OMEGA Trial. Ann. Rheum. Dis. 1 Suppl (2004) 91
8. Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43 (2000) 1001-1009
9. den Broeder A.A., de Jong E., Franssen M.J., Jeurissen M.E., Flendrie M., and van den Hoogen F.H. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann. Rheum. Dis. 65 (2006) 760-762
10. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann. Rheum. Dis. 4 Suppl (2005) 2-14
11. Solau-Gervais E., Laxenaire N., Cortet B., Dubucquoi S., Duquesnoy B., and Flipo R.M. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatol. 45 (2006) 1121-1124
12. Buch M.H., Bingham S.J., Seto Y., McGonagle D., Bejarano V., White J., et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum. 50 (2004) 725-728
13. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50 (2004) 1412-1419
14. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002) 614-624
15. Dayer J.M. Interleukin-1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?. J. Rheumatol. 65 (2002) 10-15
16. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., and Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52 (2005) 1794-1803
17. Haraoui B., Bourrelle D., and Kaminska E. Anakinra in the treatment of adult-onset Still's disease. Ann. Rheum. Dis. 2 Suppl 2 (2004) 293
18. Quartier P., Lequerré T., Rosellini D., Sibilia J., Debandt M., Kone-Paut I., et al. Anakinra in systemic-onset juvenile idiopathic arthritis and adult onset Still's disease. Ann. Rheum. Dis. 2 Suppl (2006) 107
19. Verbsky J.W., and White A.J. Effective use of the recombinant interleukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31 (2004) 2071-2075
20. Pascual V., Allantaz F., Arce E., Punaro M., and Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201 (2005) 1479-1486
21. Frenkel J., Rijkers G.T., Mandey S.H., Buurman S.W., Houten S.M., Wanders R.J., et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46 (2002) 2794-2803
22. Rigante D., Ansuini V., Caldarelli M., Bertoni B., La Torraca I., and Stabile A. Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv. Syst. 22 (2006) 334-337
23. Hawkins P.N., Lachmann H.J., Aganna E., and McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50 (2004) 607-612
24. Lovell D.J., Bowyer S.L., and Solinger A.M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52 (2005) 1283-1286
25. Rynne M., Maclean C., Bybee A., McDermott M.F., and Emery P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin-1 receptor antagonism. Ann. Rheum. Dis. 65 (2006) 533-534
26. de Koning H.D., Bodar E.J., Simon A., van der Hilst J.C., Netea M.G., and van der Meer J.W. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann. Rheum. Dis. 65 (2006) 542-544
27. Moosig F., Zeuner R., Renk C., and Schroder J.O. IL-1RA in refractory systemic lupus erythematosus. Lupus 13 (2004) 605-606
28. Ostendorf B., Iking-Konert C., Kurz K., Jung G., Sander O., and Schneider M. Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64 (2005) 630-633
29. Vounotrypidis P., Sakellariou G.T., Zisopoulos D., and Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatol. 45 (2006) 491-492
30. Chevalier X., Giraudeau B., Conrozier T., Marliere J., Kiefer P., and Goupille P. Safety study of intraarticular injection of interleukin-1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32 (2005) 1317-1323
31. Tan A.L., Marzo-Ortega H., O'Connor P., Fraser A., Emery P., and McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann. Rheum. Dis. 63 (2004) 1041-1045
32. Haibel H., Rudwaleit M., Listing J., and Sieper J. Open-label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. 64 (2005) 296-298
33. Wendling D. Interleukin-1: a new therapeutic target for ankylosing spondylitis?. Joint Bone Spine 72 (2005) 357-358